Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product

CT-P10 (Truxima™) was recently approved as the world's first rituximab biosimilar product in the European Union (EU) and South Korea. To demonstrate biosimilarity of CT-P10 with the reference medicinal product (RMP), extensive 3-way similarity assessment has been conducted between CT-P10, EU-Ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyoung Hoon, Lee, Jihun, Bae, Jin Soo, Kim, Yeon Jung, Kang, Hyun Ah, Kim, Sung Hwan, Lee, So Jung, Lim, Ki Jung, Lee, Jung Woo, Jung, Soon Kwan, Chang, Shin Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916562/
https://www.ncbi.nlm.nih.gov/pubmed/29469653
http://dx.doi.org/10.1080/19420862.2018.1433976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916562/
https://www.ncbi.nlm.nih.gov/pubmed/29469653
http://dx.doi.org/10.1080/19420862.2018.1433976

Ejemplares similares